Chemung Canal Trust Co. lowered its stake in Allergan PLC. (NYSE:AGN) by 4.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,194 shares of the company’s stock after selling 836 shares during the period. Chemung Canal Trust Co.’s holdings in Allergan PLC. were worth $4,108,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. Crestwood Advisors Group LLC bought a new position in Allergan PLC. during the first quarter valued at approximately $103,000. Feltz Wealth PLAN Inc. acquired a new stake in Allergan PLC. during the first quarter worth $107,000. Enterprise Financial Services Corp boosted its stake in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after buying an additional 178 shares in the last quarter. JNBA Financial Advisors boosted its stake in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares in the last quarter. Finally, Webster Bank N. A. boosted its stake in Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock worth $124,000 after buying an additional 123 shares in the last quarter. Institutional investors and hedge funds own 84.77% of the company’s stock.

Allergan PLC. (NYSE:AGN) traded up 1.5144% on Tuesday, hitting $244.8731. The stock had a trading volume of 654,894 shares. The company has a 50 day moving average of $245.21 and a 200 day moving average of $237.12. The company has a market capitalization of $82.24 billion, a PE ratio of 7.6299 and a beta of 1.16. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. Allergan PLC.’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the business posted $3.35 earnings per share. On average, equities analysts expect that Allergan PLC. will post $16.21 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.16%. Allergan PLC.’s payout ratio is 9.95%.

TRADEMARK VIOLATION NOTICE: “Chemung Canal Trust Co. Has $4.11 Million Stake in Allergan PLC. (NYSE:AGN)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/08/chemung-canal-trust-co-has-4-11-million-stake-in-allergan-plc-nyseagn.html.

AGN has been the subject of a number of recent analyst reports. Royal Bank Of Canada set a $279.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Wednesday, April 12th. Mizuho dropped their price target on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Cowen and Company set a $400.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. UBS AG reaffirmed a “buy” rating and set a $275.00 price target on shares of Allergan PLC. in a report on Monday, May 15th. Finally, Citigroup Inc. raised their price target on Allergan PLC. to $261.00 and gave the company a “buy” rating in a report on Monday, April 24th. Seven analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $274.14.

In related news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.36% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.